hpski

Top Biotech Picks for ASCO 2009 (Part II)

This is a follow up to my previous post. Genmab will indeed be represented at ASCO. See below:

OFATUMUMAB AND R1507 DATA TO BE PRESENTED AT ASCO

Copenhagen, Denmark; May 11, 2009 – Genmab A/S (OMX: GEN) announced today that data from the ofatumumab and R1507 development programs will be presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 29-June 2 in Orlando, Florida.



Ofatumumab – Poster session, May 30 from 8AM to 12PM EDT

Abstract # 7044 Ofatumumab, a novel CD20 mAb, is active regardless of prior rituximab exposure in patients with fludarabine- and alemtuzumab-refractory or bulky fludarabine-refractory chronic lymphocytic leukemia (CLL).



Ofatumumab – Poster session, May 30 from 8AM to 12PM EDT

Abstract # 7043 Clinical improvement with a novel CD20 mAb, ofatumumab, in fludarabine-refractory chronic lymphocytic leukemia (CLL) also refractory to alemtuzumab or with bulky lymphadenopathy.



R1507 – Oral presentation, June 1 at 3PM EDT

Abstract # 10503 A SARC global collaborative Phase II trial of R1507, a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R) in patients with recurrent or refractory sarcomas.



R1507 – Poster session, May 30, 2PM to 6PM EDT

Abstract # 8095 Expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507)



The full abstracts will be available at asco.org on May 14, 2009.

Top Biotech Picks for ASCO 2009 (Part II)

This is not an ASCO issue, however ASCO is overshadowing the development reprinted below. I fully expect ODAC to recommend approval. Furthermore, I am sure that Arzerra was the main reason Biogen Idec puT themselves up for sale last year, and the main reason there were no takers at their asking price.

FDA Advisory Committee to Review Arzerra(TM) (Ofatumumab)
11:05a ET May 4, 2009 (GlobeNewswire)

Genmab A/S (OMX:GEN) announced today that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) will hold a meeting on May 29, 2009 to review the Arzerra(TM) (ofatumumab) Biologics License Application (BLA) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received prior therapy.

Genmab and GlaxoSmithKline submitted the BLA in January 2009 and announced that the FDA accepted it for review in April 2009. The FDA has granted ofatumumab priority review status.